Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement

  • STATUS
    Recruiting
  • End date
    Feb 7, 2023
  • participants needed
    20000
  • sponsor
    Dartmouth-Hitchcock Medical Center
Updated on 7 September 2020
Investigator
Carol A Lambourne, PhD
Primary Contact
Sinai Hospital (7.7 mi away) Contact
+34 other location
aspirin
warfarin
anticoagulants
rivaroxaban
total knee replacement
embolism

Summary

PEPPER is a randomized study comparing the three most commonly used anticoagulants in North America in patients who have elected to undergo primary or revision hip or knee joint replacement surgery. The anticoagulants being compared are enteric coated aspirin, low intensity warfarin, and rivaroxaban.

Description

PEPPER is a large pragmatic clinical trial to inform patient choice and balance risk tolerances of individuals who face decisions about different drugs and strategies for deep vein thrombosis (DVT) and pulmonary embolism (PE) prevention after total hip (THA) and knee (TKA) replacement. Indeed, clinical equipoise exists to ethically support such a randomized trial that has great potential to change current practice. We have selected the three prophylaxis methods that represent current orthopaedic practice in North America and collectively account for more than 80% of all hip and knee replacements; a) enteric coated aspirin (regimen with lowest bleeding risk; clinical PE and all-cause mortality rates comparable to more intensive anticoagulants), b) low intensity (INR Target 2.0) warfarin (time honored and one of the most common North American regimens; low bleeding risk [1-2%]), and c) rivaroxaban, a new oral direct Factor Xa inhibitor (regimen with lowest PE and DVT rate but higher bleeding risk [3-5%]). Prophylaxis will continue for 30 days, in accordance with clinical guidelines, and pneumatic compression will be utilized in hospital in conjunction with each treatment group. Each regimen is commonly used in contemporary practice, supported by observational and clinical trial data, and endorsed by the American College of Chest Physicians (ACCP) and American Academy of Orthopaedic Surgeons (AAOS) guidelines

Details
Treatment Rivaroxaban, Warfarin, Enteric Coated Aspirin
Clinical Study IdentifierNCT02810704
SponsorDartmouth-Hitchcock Medical Center
Last Modified on7 September 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 21 yrs?
Gender: Male or Female
Do you have any of these conditions: Venous Thrombosis or Pulmonary Embolism or Pulmonary Disease or Thromboembolism or Blood Clots or Deep Vein Thrombosis or Thrombosis or Lung Disease?
21 years of age or older
Undergoing elective primary, revision or second stage re-implantation total hip/knee replacement or uni-compartmental knee replacement or hip resurfacing arthroplasty
Has necessary mental capacity to participate and is able to comply with study protocol requirements
Eligible for randomization to at least two of the three study regimens
Is not pregnant on the day of surgery
Has signed the consent form; and
Is willing to be randomized and participate in the study

Exclusion Criteria

Undergoing bilateral hip or knee replacement
Has been previously enrolled
Is pregnant or breastfeeding
Is on chronic anticoagulation other than antiplatelet medications
Concurrently enrolled in another active interventional clinical trial testing a drug or intervention known or believed to interact with aspirin, warfarin, or rivaroxaban
Has documented gastrointestinal, cerebral, or other hemorrhage within 3 months
Has a known diagnosis of defective hemostasis and past history of clinical bleeding requiring transfusion and treatment
Has had an operative procedure involving the eye, ear, or central nervous system within one month
Has uncontrolled hypertension with systolic BP > 220mmHg or diastolic BP > 120mmHg
Body weight of less than 41 kilograms at baseline visit
Member of a vulnerable patient population
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet